Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Emerging Pharmaceutical Therapies to Address the Inadequacy of Gluten-Free Diet for Celiac Disease

Martina Crepaldi
ORCID logo ,
Michela Palo
,
Daria Maniero
,
Luisa Bertin
,
Edoardo Vincenzo Savarino
ORCID logo ,
Robert Paul Anderson
,
Fabiana Zingone
* ORCID logo
Version 1 : Received: 4 November 2023 / Approved: 6 November 2023 / Online: 6 November 2023 (13:44:55 CET)

A peer-reviewed article of this Preprint also exists.

Crepaldi, M.; Palo, M.; Maniero, D.; Bertin, L.; Savarino, E.V.; Anderson, R.P.; Zingone, F. Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease. Pharmaceuticals 2024, 17, 4. Crepaldi, M.; Palo, M.; Maniero, D.; Bertin, L.; Savarino, E.V.; Anderson, R.P.; Zingone, F. Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease. Pharmaceuticals 2024, 17, 4.

Abstract

.Celiac disease (CeD) is a chronic, autoimmune disorder triggered by the ingestion of gluten, affecting around 1% of the global population. It is a multifactorial disease involving both genetics and environ-mental factors. Nowadays, the only available treatment for CeD is a life-long gluten-free diet (GFD), which can cause a significant burden for patients, since symptoms and mucosal injury can persist de-spite apparent compliance with a GFD. That could also lead to psychological consequences and affect the quality of life of these patients. Thankfully, recent advances in understanding the pathogenesis of CeD and the availability of various targets have made it feasible to explore pharmaceutical treatments specific to CeD. Recently, the FDA has highlighted the unmet needs of adult patients on GFD who expe-rience ongoing symptoms attributed to CeD and also show persistent duodenal villous atrophy. This re-view will outline the limitations of a GFD, describe the targets of potential novel treatment of CeD and provide an overview of the primary clinical trials involving oral and injectable agents for a non-dietary treatment of CeD.

Keywords

celiac disease (CeD); gluten-free diet (GFD); novel treatment; non-dietary treatment

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.